Explain It to Me Please

2026Q3 Tempus AI Inc. (TEM)

November 6, 2026·41 min
Episode Description from the Publisher

Tempus AI operates a dual-engine business model at the intersection of genomic sequencing, precision oncology, and artificial intelligence. The company aims to construct the world’s largest library of clinical and molecular data and operationalize that data to personalize patient care and accelerate therapeutic discovery. The business is bifurcated into two highly synergistic segments: Diagnostics and Data and Applications.Primary Businesses and Operations:Diagnostics: Tempus provides next-generation sequencing (NGS) and molecular profiling directly to oncologists and pathologists. Its core assays include xT (a 648-gene solid tumor DNA assay), xR (a whole-transcriptome RNA solid tumor assay), xF (a liquid biopsy assay), and xM (a methylation-based assay for minimal residual disease detection)7. This segment operates as the data-gathering engine. While gross margins in Diagnostics are solid (historically ~50-60%), the true value lies in the data generated from every test.Data and Applications: Tempus anonymizes, structures, and harmonizes the clinical and genomic data gathered by the Diagnostics division, packaging it into a proprietary, multimodal database. This data is then licensed to biopharmaceutical giants (e.g., AstraZeneca, GSK, Pfizer, BioNTech) to optimize clinical trial design, identify novel biomarkers, and create synthetic control arms9. This segment operates essentially as a high-margin Data-as-a-Service (DaaS) business.Industry Trends, Competitive Trends, and Market Potential (TAM): The total addressable market (TAM) for targeted sequencing, resequencing, and minimal residual disease (MRD) monitoring is experiencing secular tailwinds. The targeted sequencing market is projected to reach $27.37 billion by 2030, compounding at 22.78% annually11. The industry trend is moving decisively from tissue-based biopsies to liquid biopsies and serial MRD testing, which allows oncologists to monitor cancer recurrence from a simple blood draw. Tempus's pending acquisition of Personalis and its NeXT Personal assay (an ultra-sensitive, whole-genome, tissue-informed MRD test) is a direct strategic maneuver to capture market share in this high-frequency testing verticalEconomic Moat:Tempus benefits from a profound data network effect. The barrier to entry in the Data and Applications segment is insurmountable for traditional diagnostic labs; a competitor would need to sequence hundreds of thousands of patients, build complex electronic health record (EHR) integrations to extract longitudinal clinical outcome data, and develop the AI infrastructure to harmonize the two. Furthermore, Tempus is actively defending its intellectual property, leveraging patent portfolios to protect its algorithmic models, establishing a deep, structural moat.

Podzilla Summary coming soon

Sign up to get notified when the full AI-powered summary is ready.

Get Free Summaries →

Free forever for up to 3 podcasts. No credit card required.

Listen to This Episode

Get summaries like this every morning.

Free AI-powered recaps of Explain It to Me Please and your other favorite podcasts, delivered to your inbox.

Get Free Summaries →

Free forever for up to 3 podcasts. No credit card required.